BUZZ-Foghorn因取消礼来支持的药物项目而股价暴跌10月1日 - ** 抗癌药物制造商Foghorn Therapeutics(FHTX.O)的股价在盘前交易中下跌44%,至2美元
** 若当前价位维持不变,该股开盘价将创历史新低
** 该公司表示,已终止(link) 与制药巨头礼来公司(LLY.N)合作开发的一种实验性抗癌药物的研发
** 由于FHD-909药物在早期临床试验中未能显示出足够的疗效,双方将不会延长其2021年的合作关系,该合作最初估值高达16亿美元
** FHTX将裁减 约40%的员工;预计将产生约230万美元的裁员相关费用
** 该公司表示将专注于自身在血液癌和前列腺癌治疗领域的研发管线
** 截至上一交易日收盘,该公司股票今年以来累计下跌34%
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.